The renin-angiotensin-aldosterone system in atrial fibrillation: A new therapeutic target?

Journal of Human Hypertension

Volumn 18, Issue 7, 2004, Pages 461-465

  Freestone, B ^a   Beevers, D G ^a   Lip, G Y H ^a  

^a UNIVERSITY DEPARTMENT OF MEDICINE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALDOSTERONE; AMIODARONE; AMLODIPINE; ANGIOTENSIN; ANGIOTENSIN 2 RECEPTOR ANTAGONIST; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTICOAGULANT AGENT; ATENOLOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CAPTOPRIL; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; IRBESARTAN; LISINOPRIL; LOSARTAN; METOPROLOL; PINDOLOL; PLACEBO; PROPRANOLOL; RAMIPRIL; RENIN; TIMOLOL; TRANDOLAPRIL;

BLOOD PRESSURE REGULATION; BODY WEIGHT DISORDER; BRADYCARDIA; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL TRIAL; COMORBIDITY; DIABETES MELLITUS; DOSE RESPONSE; DRUG EFFICACY; DRUG MECHANISM; DRUG TARGETING; HEART ATRIUM FIBRILLATION; HEART LEFT VENTRICLE HYPERTROPHY; HUMAN; HYPERTENSION; INCIDENCE; NOTE; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; RISK FACTOR; STROKE; THROMBOGENESIS; TREATMENT OUTCOME; WEIGHT GAIN;

ADRENERGIC BETA-ANTAGONISTS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ATRIAL FIBRILLATION; HUMANS; RENIN-ANGIOTENSIN SYSTEM;

EID: 3142513562     PISSN: 09509240     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.jhh.1001694     Document Type: Note

References (29)

1. The Heart Outcomes Protection Evaluation Study Investigators. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Eng J Med 2000; 342: 145-153.
2. Remme WJ, Swedberg K. Guidelines for the diagnosis and treatment of chronic heart failure. Eur Heart J 2001; 22: 1527-1560.
3. Packer M et al. Comparative effects of low and high doses of the angiotensin-converting enzyme inhibitor, lisinopril, on morbidity and mortality in chronic heart failure. Circulation 1999; 100: 2312-2318.
4. Dahlof B et al. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomized trial against atenolol. Lancet 2002; 359: 995-1003.
5. Dahlof B, Hornestam B, Aurup P. on behalf of the LIFE study group, Losartan decreases the risk of stroke in hypertensive patients with atrial fibrillation and left ventricular hypertrophy. Eur Heart J 2002; 23 (abstract suppl): 412 (abstract).
6. Kober L et al. A clinical trial of the angiotensin converting enzyme inhibitor trandolapril in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 1995; 333: 1670-1676.
7. Pedersen OD et al. Trandolapril reduces the incidence of atrial fibrillation after acute myocardial infarction in patients with left ventricular dysfunction. Circulation 1999; 100: 376-380.
8. MRC Working Party. Medical Research Council trial of treatment of hypertension in older adults: principal results. BMJ 1992; 304 (6824): 405-412.
9. UK Prospective Diabetes Study Group. Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 39. BMJ 1998; 317 (7160): 713-720.
10. Freemantle N et al. Beta blockade after myocardial infarction: systematic review and meta regression analysis. BMJ 1999; 318 (7200): 1730-1737.
11. Nishimura Y, Ito T, Saavedra JM. Angiotensin II AT(1) blockade normalizes cerebrovascular autoregulation and reduces cerebral ischaemia in spontaneously hypertensive rats. Stroke 2000; 31: 2478-2486.
12. Deary AJ et al. Influence of drugs and gender on the arterial pulse wave and natriuretic peptide secretion in untreated patients with essential hypertension. Clin Sci 2002; 103: 493-499.
13. Panza JA et al. Abnormal endothelium-dependent vascular relaxation in patients with essential hypertension. N Engl J Med 1990; 323: 22-27.
14. Mondillo S et al. Correlation between left atrial size, prothrombotic state and markers of endothelial dysfunction in patients with lone non-rheumatic chronic atrial fibrillation. Int J Cardiol 2000; 75: 227-232.
15. Stoddard ME, Dawkins PR, Prince CR, Ammash NM. Left atrial appendage thrombus is not uncommon in patients with acute atrial fibrillation and a recent embolic event: a transesophageal echocardiographic study. J Am Coll Cardiol 1995; 25: 452-459.
16. Goette A et al. Regulation of angiotensin II receptor subtypes during atrial fibrillation in humans. Circulation 2000; 101: 2678-2781.
17. Nakashima H et al. Angiotensin II antagonist prevents electrical remodeling in atrial fibrillation. Circulation 2000; 101: 2612-2617.
18. Lip GYH. Does atrial fibrillation confer a hypercoagulable state? Lancet 1995; 346: 1313-1314.
19. Nadar S, Lip GYH. The prothrombotic state in hypertension and the effects of antihypertensive treatment. Curr Pharm Des 2003; 9 (21): 17 15-1732.
20. Vaughan DE, Lazos S, Tong K. Angiotensin II regulates the expression of plasminogen activator inhibitor-type 1 in cultured endothelial cells. A potential link between the renin-angiotensin system and thrombosis. J Clin Invest 1995; 95: 995-1001.
21. Ridker PM, Gaboury CL, Conlin PR et al. Stimulation of plasminogen activator inhibitor in vivo by infusion of angiotensin II. Evidence of a potential interaction between the renin-angiotensin system and fibrinolytic function. Circulation 1993; 87: 1969-1973.
22. Goodfield NER et al. Effect of acute angiotensin II type 1 receptor antagonism and angiotensin converting enzyme inhibition on plasma fibrinolytic parameters in patients with heart failure. Circulation 1999; 99: 2983-2985.
23. Erdem Y et al. Effects of angiotensin converting enzyme and angiotensin II receptor inhibition on impaired fibrinolysis in systemic hypertension. Am J Hypertens 1999; 12: 1071-1076.
24. Vaughan DE et al. Effects of ramipril on plasma fibrinolytic balance in patients with acute myocardial infarction. HEART study investigators. Circulation 1997; 96: 442-447.
25. Webster MWI et al. Effect of enalapril on ventricular arrhythmias in congestive heart failure. Am J Cardiol 1985; 56: 566-569.
26. Waktare JEP et al. The role of atrial ectopics in initiating paroxysmal atrial fibrillation. Eur Heart J 2001; 22: 333-339.
27. Van de Berg MP et al. Effects of lisinopril in patients with heart failure and chronic atrial fibrillation. J Card Failure 1995; 1: 355-363.
28. Madrid AH et al. Use of Irbesartan to maintain sinus rhythm in patients with long-lasting persistent atrial fibrillation. Circulation 2002; 106: 331.
29. Channer KS, James MA, MacConnell T, Rees JR. β-Adrenoreceptor blockers in atrial fibrillation: the importance of partial agonist activity. Br J Pharmac 1994; 37: 53-57.